3Tumidge J, Bell J, Biedenbach D J, et al. Pathogen ocurrence and antimicmbia resistance trends amtmg urinary tract infection isolates in the Asia-Western Pacific Region: report from the SENTRY Anfimicmbial Surveillanceogrddm [J]. 1998- 1999. Hat J Antimicrob Agents, 2002,20( 1 ) .. 10. 被引量：1
4Mingiot-Leclercq M P,Glupezynski Y,Tulkens P M. Amino- glycosides:activity and resistanee[J]. Antimicmb Agents Chemoth- er, 1999,43 : 727. 被引量：1
5Moore R D, Smith C R, Lietman P. Clinical response to ami- noglycoside therapy: Importance of theration of peak concentra- tion minimal inhibitory concentration[J]. J lnfeet Dis, 1987, 155: 93. 被引量：1
6Nightingale C H,Murakawa T,Ambrose P C,et al. Antimicro- bial pharmacodynamics in theory and clinical practice[J]. New York : Marcel Dekker, InC, 2002,385-408. 被引量：1
7Yano H, Kuga A, Okalnoto R, et al. Plasmid-encodextmetallo- 13-1actamase(IMP-6)conferring resistance to carbapenem,especially meropenem[J]. Antinficrob Agents Chemother,2001,45(5) : 1343. 被引量：1
2[3]Thoma GV. Beta-lactam antibiotics: is continuous infusion the preferred method of administration? The Annals of Pharmacotherapy, 1995, 29: 415. 被引量：1
5[6]Zhao X, Drlica K. Restricting the selection of antibiotic resistant mutants: a general strategy derived form fluoro quinolone studies. Clini Infect Dis, 2001, 33 (suppl 3):S147. 被引量：1
6[7]Zhao X, J Drlica . Restricting the selection of antibiotic resistant mutant bacteria: measurement and potential use ofthe mutant selection window. The Journal of Infectious Diseases,2002, 35: 561. 被引量：1
7[8]Craig WA, Ebert SC. Killing and regrowth of bacteria in vitro. Scand J Infect Dis , Suppl 1991, 74: 63. 被引量：1
8[9]Ursula Fluckiger et. Integration of Pharmacokinetics and Phrmacodynamics of Imipenem in a Human -Adapted Mouse Model. Antimicrobiol Agents and Chemotherapy, 1991, 35: 1905. 被引量：1
9[10]Bennett Vogelman et. Kinetics of antimicrobiol activity. The Journal of Pediatric, 1986, 108: 835. 被引量：1
10[11]CraigWA. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad- spectrum cephalosporins. Diagn Microbiol Infect Dis, 1995, 22: 89. 被引量：1
